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Abstract
Introduction: The important protective role of small heat-shock proteins (HSPs) in regulating cellular survival and
migration, counteracting protein aggregation, preventing apoptosis, and regulating inflammation in the central nervous
system is now well-recognized. Yet, their role in the neuroinflammatory disorder multiple sclerosis (MS) is largely
undocumented. With the exception of alpha B-crystallin (HSPB5), little is known about the roles of small HSPs in disease.
Results: Here, we examined the expression of four small HSPs during lesion development in MS, focussing on their
cellular distribution, and regional differences between white matter (WM) and grey matter (GM). It is well known that
MS lesions in these areas differ markedly in their pathology, with substantially more intense blood-brain barrier damage,
leukocyte infiltration and microglial activation typifying WM but not GM lesions.
We analysed transcript levels and protein distribution profiles for HSPB1, HSPB6, HSPB8 and HSPB11 in MS lesions at
different stages, comparing them with normal-appearing brain tissue from MS patients and non-neurological controls.
During active stages of demyelination in WM, and especially the centre of chronic active MS lesions, we found significantly
increased expression of HSPB1, HSPB6 and HSPB8, but not HSPB11. When induced, small HSPs were exclusively found in
astrocytes but not in oligodendrocytes, microglia or neurons. Surprisingly, while the numbers of astrocytes displaying
high expression of small HSPs were markedly increased in actively demyelinating lesions in WM, no such induction was
observed in GM lesions. This difference was particularly obvious in leukocortical lesions covering both WM and GM areas.
Conclusions: Since induction of small HSPs in astrocytes is apparently a secondary response to damage, their
differential expression between WM and GM likely reflects differences in mediators that accompany demyelination in
either WM or GM during MS. Our findings also suggest that during MS, cortical structures fail to benefit from the
protective actions of small HSPs.
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Introduction
Multiple sclerosis (MS) is a chronic demyelinating dis-
ease of the central nervous system (CNS), affecting
about 2.3 million people worldwide. Disease onset is
usually first observed in young adults and it is the most
common cause of non-traumatic disability in this age
group [1, 2]. The pathology of MS is characterized by
focal areas of inflammatory myelin damage, axonal in-
jury and axonal loss both in white matter (WM) and
grey matter (GM) [3]. Actively demyelinating WM lesions
that continuously emerge and regress during disease are
characterised by disruption of the blood-brain barrier,
marked leukocyte infiltration, and large-scale activation of
microglia/macrophages. While in the GM, demyelination
generally progresses with much less tissue infiltration and
microglial activation [4, 5]. In addition to focal lesions of
overt myelin damage, small focal clusters of activated
microglia are frequently observed in the normal appearing
white matter (NAWM) of MS patients, in the absence of
any detectable blood-brain barrier breakdown, leukocyte
recruitment or myelin damage [6, 7]. In vivo imaging
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studies support the notion that these so-called preactive
lesions may be the first, still reversible signs of inflamma-
tory damage that can precede actively demyelinating MS
lesions by several months [8, 9].
Previously, we have documented a close association
between the development of preactive MS lesions and
the presence of stressed oligodendrocytes that produce
large amounts of the small heat-shock protein (HSP)
alpha B-crystallin (also known as HSPB5) [10]. At later
stages of lesion development, high levels of HSPB5 also
emerge in astrocytes [11–13]. Elevated expression of
HSPB5 by oligodendrocytes during MS may have par-
ticular relevance since HSPB5 activates a regulatory in-
nate response by microglia via Toll-like receptor (TLR) 2
and CD14, the signs of which can already be found in
preactive lesions [10, 14]. In the presence of IFN-γ as an
additional co-stimulus, however, HSPB5 triggers a clas-
sical state of activation in microglia and macrophages,
which is characteristic of the more advanced stages of
actively demyelinating lesions [15]. HSPB5 thus offers a
molecular link between stressed oligodendrocytes and
the development of destructive inflammation. Since
other small HSP such as HSPB1 and HSPB8 have previ-
ously been reported to share TLR agonist activity with
HSPB5 [16–18], the present study addressed the ques-
tion whether small HSPs other than HSPB5 display simi-
lar expression profiles during lesional development in
MS.
The group of small HSPs consists of eleven members,
HSPB1-HSPB10 and the recently described HSPB11
[19, 20]. However, whether HSPB11 really belongs to
the family is still under debate [21]. The small HSPs
share many structural and functional similarities, yet
they differ in tissue distribution and expression pat-
terns. HSPB1, HSPB5, HSPB6, HSPB8 and HSPB11
have been described to be present in the central
nervous system either under normal condition or after
stress induction [22–25]. Since not all small HSPs
show the same response to particular types of stress
[13, 23, 24, 26], differentiating their expression
profiles may shed light on the molecular triggers that
either drive or accompany the development of MS
lesions.
In this study, we therefore evaluated by quantitative
polymerase chain reaction (qPCR) and immunohisto-
chemical staining the expression at different stages of
lesion development during MS of HSPB1, HSPB6, HSPB8
and HSPB11. We paid particular attention to the cellular
localisation of these four small HSPs, and additionally
compared their expression between WM and GM lesions.
As stated above, it has been well documented that the
histopathology of GM lesions emerging during MS differs
significantly from WM lesions. This difference has been
suggested to be due to other pathogenic mechanisms that
may operate in cortical versus white matter demyelination
[3–5, 27]. Our data reveal that HSPB1, HSPB6 and HSPB8
but not HSPB11 are induced during active stages of de-
myelination in WM lesions, and particularly so in the
centre of chronic active MS lesions. Different from
HSPB5, however, induction of the other small HSPs was
exclusively found in astrocytes and not in oligodendro-
cytes, and it was not found in preactive lesions. Further-
more, while the numbers of astrocytes displaying high
expression of small HSPs were markedly increased in ac-
tively demyelinating lesions in the WM, no such induction
was seen in GM lesions. This difference was particularly
striking in leukocortical lesions that comprise both re-
gions. Given that astrocytic expression of the small HSPs
studied here is an apparently secondary response to the
development of actively demyelinating MS lesions, their
differential expression in either WM or GM lesions likely
reflects a difference in the molecular signals that accom-




Studies were performed on post-mortem human brain tis-
sue from 18 MS cases (mean age 62, 41–87 years) and 9
age-matched non-neurological controls (mean age 67, 51–
88 years). Samples were obtained according to the protocol
of the Netherlands Brain Bank (coordinator Dr. I. Huitinga,
Amsterdam, The Netherlands), with the approval of the VU
University Medical Ethical Committee (Amsterdam, The
Netherlands). Patients and controls, or their next of kin,
had given informed consent for the use of their brain tissue
and clinical details for research purposes. Relevant patient
information is summarised in Table 1.
Real-time qPCR
Snap-frozen material of WM from control subjects and
NAWM from MS patients (Table 1A) was collected in
Eppendorf tubes containing 0.5 mL TRIzol® (Life-
Technologies, Bleiswijk, The Netherlands) and homoge-
nised. Total RNA was extracted using chloroform
following manufacturer’s instructions (Invitrogen, Breda,
The Netherlands). RNA purity and concentrations were
measured using a NanoDrop 2000 spectophotometer
(Thermo Fisher Scientific, Waltman, USA). According to
manufacturer’s instructions 1 μg of total RNA was re-
verse transcribed into cDNA (Reverse Transcription Sys-
tem, Promega) and real-time qPCR was carried out
using Sso Advanced™ universal SYBR® Green supermix
(Biorad, Veenendaal The Netherlands). The primer
sequences are listed in Table 2.
Reactions were normalized to the reference genes 18S
(data not shown) and elongation factor 1α (EF1α). Primer
pair efficiency (E) was determined using LinRegPCR
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software [28] and relative expression calculated as
E‐CT
target gene
=E‐CT reference gene . Melting curves and gel
electrophoresis were routinely performed to define the
PCR-product specificity (data not shown). All experiments
were performed in triplicate.
Lesion characterisation
MS lesions were identified by MRI-guided sampling of the
CNS as described previously [29]. For lesion characterisa-
tion 5 μm-thick paraffin sections were stained with anti-
bodies directed against myelin proteolipid protein (PLP)
and HLA-DR to detect activated microglia/macrophages.
Slides were deparaffinised in xylene and rehydrated
through descending alcohol concentrations. Endogenous
peroxidase activity was blocked by incubating the slides
30 min in phosphate buffered saline (PBS) containing
0.3 % H2O2. For HLA-DR expression the sections were
heated in 0.01 M citrate buffer (pH 6.0). After allowing
the heated sections to regain room temperature (RT),
sections were rinsed in PBS. Sections were incubated with
primary antibodies directed against PLP and HLA-DR
(Table 3) for 1 h at RT. After incubation, sections were
thoroughly rinsed in PBS and incubated with ready-to-use
goat-anti-mouse EnVision+™-HRP (Dako, Glostrup,
Denmark) for 30 min at RT. Sections were rinsed in PBS,
incubated in 3,3’-diaminobenzidine (DAB; Dako) to visual-
ise staining and counterstained with haematoxylin.
White matter MS lesions were classified according to
the degree of myelin damage and the activity of the
microglia/macrophages as described earlier [6]. Briefly,
preactive lesions were classified as a cluster of activated
(HLA-DR+) microglia in NAWM; active lesions were
characterised by a focal area of myelin loss filled with
myelin-laden ‘foamy’ macrophages; chronic active lesions
were identified by a rim of activated microglia/macro-
phages surrounding a hypocellular centre, and inactive
WM lesions as a demyelinated area with few or no
HLA-DR+ cells.
In contrast to WM, cortical demyelination during MS
is not accompanied by fulminant activation of microglia/
macrophages. Therefore, cortical lesions were classified
according to the neuroanatomical location as reported
previously [27, 30]. Lesions of myelin damage in the
white matter that extend beyond the border between
white and grey matter were classified as leukocortical le-
sions, whereas lesions completely within the cortex are
termed intracortical, and demyelination along the sur-
face of the brain as subpial. For this study 23 paraffin-
embedded tissue blocks containing 15 preactive, 8 active,
6 chronic active and 4 inactive WM lesions, and an add-
itional 5 leukocortical, 3 intracortical and 7 subpial GM
lesions were examined.
Immunohistochemical detection of HSPB1, HSPB6, HSPB8,
HSPB11
To analyse the expression of small HSPs, paraffin sec-
tions were double labelled for HLA-DR and small HSPs.
Table 1 Clinical details of MS patients and control subjects
A. Tissues used for RT-PCR analysis
Donor Age Gender PM delay
(h:m)
Diagnosis Cause of death
1 51 M 7.30 CON Euthanasia; esophageal
cancer
2 56 M 9.15 CON Myocardial infarction
3 62 M 7.20 CON Unknown
4 66 F 6.00 MS (N/A) Unknown
5 61 M 9.15 MS (SP) Euthanasia
6 50 F 7.35 MS (SP) Euthanasia
7 66 F 9.35 MS (PP) Euthanasia
B. Tissues used for immunohistochemical studies
1 51 M 7.30 CON Euthanasia; esophageal
carcinoma
2 56 M 9.15 CON Myocardial infarction
5 61 M 9.15 MS (SP) Euthanasia
6 50 F 7.35 MS (SP) Euthanasia
7 66 F 9.35 MS (PP) Euthanasia
8 82 M 6.53 CON Pleuritis carcinomatosis
9 87 M 6.32 CON Pneumonia
10 66 M 7.45 CON Ruptured abdominal aorta
aneurysm
11 88 M 7.00 CON End stage rectum and
prostate carcinoma
12 60 F 7.30 CON Infection e.c.i
13 51 M 7.45 CON Suicide
14 41 F 8.25 MS (SP) Unknown
15 43 F 10.45 MS (SP) Subdural haematoma,
pneumonia
16 56 M 8.00 MS (SP) Pneumonia
17 78 F 11.10 MS (N/A) Cerebrovascular accident
18 66 M 7.30 MS (PP) Ileus
19 77 F 10.00 MS (SP) Euthanasia
20 45 M 7.45 MS (N/A) Pulmonary embolism
21 83 M 7.50 MS (PP) Aspiration pneumonia
22 74 M 10.15 MS (N/A) Cardio-respiratory
insufficiency
23 54 M 8.15 MS (PP) Euthanasia
24 53 M 10.00 MS (SP) Euthanasia
25 56 F 8.25 MS (SP) Pneumonia
26 54 M 10.50 MS (N/A) Euthanasia
27 87 F 9.30 MS (N/A) Renal insufficiency
PM post mortem, M male, F female, CON control, MS multiple sclerosis, SP
secondary progressive, PP primary progressive, N/A not known
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Deparaffinised, rehydrated and endogenous peroxidase-
blocked slides were heated in a microwave oven for
10 min in 0.01 M citrate buffer (pH 6.0). After antigen
retrieval, sections were allowed to cool to RT and rinsed
in PBS. Subsequently, sections were incubated overnight
at RT with primary antibodies directed to HLA-DR and
HSPB1, HSPB6, HSPB8 or HSPB11 (Table 3). After the
sections were rinsed, the relevant secondary antibodies
[goat-anti-mouse-alkaline phosphatase (AF labelled
(Southern Biotech, AL, USA) or goat-anti-rabbit EnVi-
sion+™ -HRP (Dako)] were applied for 1 h at RT. Cells
labelled with HRP were visualised with DAB, whereupon
slides were rinsed in Tris buffered saline (TBS) to detect
AF-labelled cells with liquid permanent red substrate-
chromogen (Dako). The sections were counterstained
with haematoxylin prior to permanent mounting in
Aquatex (Merck, Darmstadt, Germany). Negative con-
trols were performed by eliminating the primary anti-
bodies and by replacing the primary antibodies by
appropriate isotype controls, viz. mouse IgG2b (BD Bio-
science, Breda, the Netherlands) or rabbit IgG (Abcam,
Cambridge, UK).
Quantitative analysis
Lesions were selected based on the integrity of myelin as
judged by PLP expression and the presence of HLA-DR+
cells. Areas within the lesion were selected randomly
and pictures of the same areas were taken in sequential
sections double stained for the selected small HSPs and
HLA-DR. Pictures were taken with a Leica DC500 (Leica
Microsystems, Heidelberg, Germany) at 200× magnifica-
tion. ImageJ software [31] was used to analyse the pic-
ture, numbers of nuclei and positive cells were counted
manually using the cell-counter plugin (de Vos, University
of Sheffield, UK). Taking into account that, as a result of
differences in levels of infiltration, the absolute numbers of
cells per area differ between white and grey matter as well
as between the distinct lesion types, immune positive cells
are presented as relative numbers to total number of nu-
clei. All nuclei visible on the pictures were counted, with
the exception of those contained within blood vessels. To
verify accuracy of the data, 18 pictures were counted by
two independent observers and inter-observer consistency
was evaluated, resulting in a correlation coefficient of 0.99.
Double immunolabelling
To identify the cells expressing the selected small HSPs,
double labelling with antibodies directed to glial fibrillary
acidic protein (GFAP), an astrocytic marker, or Olig2, an
oligodendroglial marker, was performed. Double labelling
of paraffin wax sections was carried out sequentially as
follows. Deparaffinised sections were subjected to antigen
retrieval and incubated overnight with primary antibodies
directed to GFAP or Olig2 (Table 3). After thorough rins-
ing, goat-anti-mouse Alexa594-labelled (Life technologies,
OR, USA) and goat-anti-rabbit-EnVision+™ -HRP-labelled
secondary antibodies for GFAP and Olig2 respectively
were incubated at RT for 1 h. DAB chromogen was used
Table 2 Primer sequences
Markers GeneID Sequence forward Sequence reverse Size (bp) Annealing temperature (°C)
HSPB1 3315 ACGGTCAAGACCAAGGATGG AGCGTGTATTTCCGCGTGA 104 58
HSPB6 126393 TGCTAGACGTGAAGCACTTCT ACCACCTTGACAGCAATTTCC 49 64
HSPB8 26353 CTCCTGCCACTACCCAAGC GGCCAAGAGGCTGTCAAGT 123 64
HSPB11 51668 TGATGGCTCCGCTACTTACTT GCAGAAACGCTATGCACAGAT 78 60
EF1α 1915 AAGCTGGAAGATGGCCCTAAA AAGCGACCCAAAGGTGGAT 116 55–62
18S 100008588 GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGCG 150 58–65
Table 3 Antibodies used for immunohistochemistry
Antigen Clone Species Isotype Dilution Antigen retrieval Manufacturer
PLP Plpc1 Mouse IgG2a 1:3000 none AbD Serotec
HLA-DR LN3 Mouse IgG2b 1:1000 Citrate buffer eBioscience
Olig2 Polyclonal Rabbit 1:200 Citrate buffer Millipore
GFAP 6 F2 Mouse IgG1 1:200 Citrate buffer Monosan
HSPB1 EPR7278 Rabbit IgG 1:500 Citrate buffer Abcam
HSPB5 JAM01 Mouse IgG1 1:100 Citrate buffer In house
HSPB6 EPR14458 Rabbit IgG 1:500 Citrate buffer Abcam
HSPB8 Polyclonal Rabbit 1:500 Citrate buffer Abcam
HSPB11 polyclonal Rabbit 1:50 Citrate buffer (20 min) Novus
PLP proteolipid protein, HLA-DR human leukocyte antigen, GFAP glial fibrillary acid protein, HSPB heat shock protein B
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to visualise HRP-labelled oligodendrocytes. Given that
antibodies directed to both Olig2 and the small HSPs are
produced in rabbits, an additional antigen retrieval step
after the DAB visualisation was performed. After which,
sections were incubated with antibodies directed against
HSPB1, HSPB5, HSPB6, HSPB8 or HSPB11 at RT for
24 h. After washing, the secondary antibodies goat-anti-
rabbit Alexa-488 (Life technologies, OR, USA) for GFAP
and goat-anti-rabbit-AF (Southern Biotech, AL, USA) for
Olig2 double labelling were allowed to bind for 1 h at RT.
Liquid permanent red (LPR) substrate was used to detect
AF-labelled cells. Sections were counterstained with
haematoxylin for the immunohistochemical procedure or
with 0.2 μg/mL 4’,6-diamidino-2-phenylindole (DAPI;
Invitrogen) in PBS for the immunofluorescence protocol.
To examine whether cells expressed more than one small
HSP, sections were also double labelled for combinations
of two small HSPs. Immunohistochemistry was performed
as explained above for double staining with Olig2 using
the relevant antibodies for HSPB1, HSPB5 and HSPB8 to
interact with HRP-labelled secondary antibodies and visu-
alise with DAB. Thereafter slides were heated in citrate
buffer (pH 6.0) at 90 °C and antibodies for HSPB1, HSPB5
or HSPB6 were used to interact with AP-labelled anti-
bodies and visualised with LPR. Immunofluorescence pic-
tures were taken using a Leica DM 5500 supported by
LAS-AF 3.0.0 software, immunohistochemical photo-
graphs were taken with a Leica DC500 microscope.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
software 6.0 (GraphPad Software, San Diego, CA). Data
distribution was tested for normality with the D’Agostino-
Pearson normality test. Since the data were not normally
distributed, data were analysed using non-parametric tests.
Counts from control white and grey matter were
compared to NAWM and NAGM from MS patients,
respectively, using the Mann-Whitney U test. Differences
between MS lesion types were analysed using the Kruskal-
Wallis Test. When positive, Mann-Whitney U test was
performed to test subgroups. Differences were considered
to be significant when p < 0.05.
Results
Expression of small HSPs is already enhanced in
normal-appearing white matter during MS
Transcript levels of HSPB1, HSPB6, HSPB8 and HSPB11
were determined by qPCR in WM tissue samples from
non-neurological controls and NAWM from MS pa-
tients. Transcript levels of HSPB1, HSPB6 and HSPB8
were significantly upregulated in NAWM tissue from
MS patients as compared to controls, with fold induc-
tions of 2.3, 3.8 and 1.7 respectively (p < 0.05; Fig. 1a–c).
In contrast, HSPB11 mRNA levels did not show signifi-
cant differences between the two groups (Fig. 1d). These
data are in line with several reports documenting on-
going diffuse inflammation and other abnormalities in
the NAWM of MS patients [32], including increased
levels of another member of the family of small HSPs,
viz. HSPB5 (Additional file 1: Figure S1) [33].
Expression of HSPB1 in white matter MS lesions
To examine in more detail the expression pattern of
HSPB1 in WM lesions from MS patients, we first
Fig. 1 Transcript levels of small heat shock proteins in control white matter and NAWM in MS patients. Real time PCR analysis of transcripts encoding
HSPB1 (a), HSPB6 (b), HSPB8 (c) and HSPB11 (d) comparing white matter from non-neurological controls (n = 3) and MS patients (n = 4). Data represent
mean ± SEM and are expressed relative to the housekeeping gene EF-1α. *p < 0.05
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performed double staining for PLP and HLA-DR to
evaluate the extent of demyelination and microglial/
macrophage activation, respectively. Double immunola-
belling was thereafter performed using antibodies di-
rected against HSPB1 and HLA-DR. This approach
enabled the identification of the different lesion types. A
total of 15 preactive, 8 active, 6 chronic active and 4 in-
active lesions were compared to 5 areas of NAWM. In
addition, 7 tissue blocks from non-neurological controls
were analysed.
Marginal expression of HSPB1 was detected in the
parenchyma of control WM, with only 1 % of the nu-
clei showing a cytoplasmic staining pattern (Fig. 2a,
i). However, intense expression was detected in the
endothelial and smooth muscle layers of both smaller
and larger blood vessels in controls (data not shown).
A similar pattern was observed in the NAWM of MS
patients, where HSPB1 was expressed in blood vessels
but scarcely in the parenchyma (Fig. 2b, i). In actively
demyelinating lesions, prominent HSPB1 immunore-
activity was exclusively associated with astrocytes as
demonstrated by GFAP co-localization (Fig. 2j–l), and
supported by the astrocytic morphology of HSPB1+
cells (Fig. 2e–h). In contrast, HSPB1 expression was
not associated with oligodendrocytes or microglia, as
evidenced by the lack of any co-localization between
Fig. 2 HSPB1 expression in white matter MS lesions. Representative images of white matter tissues from non-neurological controls (a) and MS
cases (b–h) double labelled for HLA-DR (pink) and HSPB1 (brown). NAWM (b), NAWM surrounding a preactive lesion (c), preactive lesion (d), active
lesion (e), chronic active lesion (f- rim, g - centre) and inactive lesions (h) from MS cases. Quantification of HSPB1+ cells in lesion areas (i). GFAP+
astrocytes co-localise with HSPB1 (j–l), while Olig2+ oligodendrocytes (m) or HLA-DR+ microglia (m) do not express HSPB1. Percentages of cells in
each area (i). Data are shown as mean ± SEM. Significance was analysed between the control and NAWM, or the NAWM group and the different
lesion types using the Mann-Whitney U test. *p < 0.05, **p < 0.01. Scale bar (a–h), (m–n) = 50 μm, (j–l) = 10 μm. CON = control, NAWM= normal
appearing white matter, PAL = preactive lesions, A = active lesion, CA = chronic active lesion, IA = inactive lesions
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HSPB1 and either Olig2 or HLA-DR, respectively
(Fig. 2m, n).
Quantitating the frequency HSPB1+ astrocytes revealed
a significant increase in the numbers of such cells in active
lesions, comparable with the increase observed at the rim
of chronic active lesions (12.5 % positive cells; Fig. 2i). The
highest frequency of HSPB1+ astrocytes was found in the
hypocellular centre of chronic active lesions, in which as
many as 25 % of all astrocytes were positive for HSPB1. In
inactive MS lesions, the frequency of HSPB1+ astrocytes
was much lower again, although still significantly higher
as compared to NAWM (p < 0.05; Fig. 2i). Sections stained
with isotype control antibodies (rabbit IgG and mouse
IgG2b) or treated while omitting the primary antibodies
were consistently negative for both MS patients and
controls (data not shown).
Expression of HSPB6 in white matter MS lesions
Similar to HSPB1, expression of HSPB6 was detected in
blood vessels in control tissue samples where the
smooth muscle cells of large vessels were positive, while
smaller vessels and endothelial cells were negative for
HSPB6. Some HSPB6 immunolabelling was also ob-
served in the parenchyma of non-neurological controls
Fig. 3 HSPB6 expression in white matter MS lesions. Representative images of white matter tissues from non-neurological controls (a) and MS cases
(b–h) double labelled for HLA-DR (pink) and HSPB6 (brown). NAWM (b), NAWM surrounding a preactive lesion (c), preactive lesion (d), active lesion
(e), chronic active lesion (f- rim, g - centre) and inactive lesions (h) from MS cases. Quantification of HSPB6+ cells in lesion areas (i). GFAP+ astrocytes
co-localise with HSPB6 (j–l), while Olig2+ oligodendrocytes (m) or HLA-DR+ microglia (n) do not express HSPB6. Percentages of cells in each area (I). Data
are shown as mean ± SEM. Mann-Whitney U tests were performed for comparisons between control white matter and NAWM and between NAWM and
the different lesion types. **p< 0.01. Scale bar (a–h, m) = 50 μm, (j–l, n) = 10 μm. CON= control, NAWM=normal appearing white matter, PAL = preactive
lesions, A = active lesion, CA = chronic active lesion, IA = inactive lesions
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(Fig. 3a) but evaluation of the frequency of astrocytes
displaying high expression of HSPB6 revealed no signifi-
cant differences between control WM (7.5 ± 2.7 %) and
NAWM in MS patients (6.7 ± 1.9 %) (Fig. 3a, b, i). Evalu-
ation of MS lesions again revealed exclusive induction of
HSPB6 in astrocytes, as confirmed by co-localization of
HSPB6 with GFAP (Fig. 3j–l) but not with Olig2
(Fig. 3m) or HLA-DR (Fig. 3n), and supported by the
morphology of HSPB6+ cells. Although a slight increase
in numbers of HSPB6+ astrocytes was observed in and
around both active and inactive lesions, the frequency of
HSPB6+ astrocytes was significantly increased relative to
control WM only in the centre of chronic active lesions
(Fig. 3g, i, p < 0.01).
HSPB8 expression in white matter MS lesions
Similar to HSPB1 and HSPB6, expression of HSPB8 was
restricted to GFAP+ astrocytes as determined by double
labelling for GFAP, and absent from Olig2+ oligodendro-
cytes or HLA-DR+ microglia (Fig. 4). In contrast to
Fig. 4 HSPB8 expression in white matter MS lesions. Representative images of white matter tissues from non-neurological controls (a) and MS cases
(b–h) double labelled for HLA-DR (pink) and HSPB8 (brown). NAWM (b), NAWM surrounding a preactive lesion (c), preactive lesion (d), active lesion
(e), chronic active lesion (f- rim, g - centre) and inactive lesions (h) from MS cases. Quantification of HSPB8+ cells in lesion areas (i). GFAP+ astrocytes
co-localise with HSPB8 (j–l), while Olig2+ oligodendrocytes (m) or HLA-DR+ microglia (n) do not express HSPB8. Percentages of cells in each area (I).
Data are shown as mean ± SEM. Mann-Whitney U tests were performed for comparisons between control white matter and NAWM and
between NAWM and the different lesion types. **p < 0.01. Scale bar (a–h) = 50 μm, (j–n) = 10 μm. CON = control, NAWM= normal appearing white
matter, PAL = preactive lesions, A = active lesion, CA = chronic active lesion, IA = inactive lesions
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HSPB1 and HSPB6, however, no vascular expression of
HSPB8 was observed (data not shown). The frequencies
of HSPB8+ astrocytes were very similar in control tissues
(6.3 ± 2.7 %, Fig. 4i), NAWM (2.8 ± 3.2 %), NAWM
close to preactive lesions (5.9 ± 5.3 %), preactive lesions
(8.15 ± 5.9 %), active lesions (6.1 ± 5.5 %), and the rim of
chronic active lesions (7.17 ± 3.4 %) (Fig. 4a–i). Like in
the case of HSPB6, a significantly increased frequency
of HSPB8+ astrocytes was only found in the centre of
chronic active lesions (19.7 ± 8.6 %, p < 0.01). In inactive
lesions the number of HSPB8+ cells was not signifi-
cantly different from NAWM (13.8 ± 8.1 %).
Expression of HSPB11 in white matter MS lesions
While some HSPB11 immunoreactivity was detected,
staining intensity was weak in control WM (Fig. 5a) as
well as in the various MS samples. Additionally, no
marked changes in areas of demyelinating lesions were
observed (Fig. 5b–h, i). In agreement with the qPCR data
(Fig. 1d), therefore, the overall expression pattern of
HSPB11 did not differ between control cases and MS
patients. When detectable, HSPB11 was exclusively found
in astrocytes (Fig. 5j–l) but not in oligodendrocytes
(Fig. 5n) or microglia (Fig. 5o). Occasionally, HSPB11+
cells appeared to resemble WM neurons (Fig. 5m).
Fig. 5 HSPB11 expression in white matter MS lesions. Images of white matter tissues from non-neurological controls (a) and MS cases (b–h) double
labelled for HLA-DR (pink) and HSPB11 (brown). NAWM (b), NAWM surrounding a preactive lesion (c), preactive lesion (d), active lesion (e), chronic active
lesion (f- rim, g - centre) and inactive lesions (h) from MS cases. Quantification of HSPB11+ cells in lesion areas (i). HSPB11 co-localises
with GFAP+ astrocytes (j–l), and is expressed by white matter neurons (m) while Olig2+ oligodendrocytes (n) or HLA-DR+ microglia
(o) do not express HSPB11. Percentages of cells in each area (i). Data are shown as mean ± SEM. Statistical analysis is performed by Mann-
Whitney U test, comparing control white matter and NAWM or NAWM and the separate lesion types, no significant differences are found.
Scale bar (a–h) = 50 μm, (j–o) = 10 μm. CON = control, NAWM = normal appearing white matter, PAL = preactive lesions, A = active lesion,
CA = chronic active lesions, IA = inactive lesions
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Expression of small HSPs in grey matter MS lesions
Demyelinating lesions in the GM differ substantially
from WM lesions with regard to the degree of visible in-
flammation as reflected by blood-brain barrier damage,
leukocyte infiltration and microglial activation [4]. To
examine whether such differences impact on the expres-
sion of small HSPs, we examined their expression in 3
intracortical lesions (from 3 different patients) and 7
subpial lesions (from 6 different patients) and compared
the results with those found for normal-appearing grey
matter (NAGM, n = 4) and GM samples collected from
non-neurological controls (n = 4; Fig. 6).
Similar to control WM, HSPB1 expression in control
GM was detected in the endothelium and smooth
muscle cells of blood vessels and leptomeningeal vessels
(data not shown). HSPB1+ cells, identified as astrocytes
by double staining for GFAP, were rarely observed in the
GM parenchyma in controls (Fig. 6a, e; 1.97 ± 1.59 %).
In the NAGM of MS patients, and even in demyelinating
cortical lesions, very similar low frequencies were found
for HSPB1+ astrocytes (Fig. 6a–e). Also when examining
expression of the other small HSPs in MS patients we
found no significant differences between demyelinating
GM lesions and NAGM (Fig. 6b–d). When detectable in
the GM, the expression of small HSPs was exclusively
confined to astrocytes again. Different from its expres-
sion profile in WM, HSPB6 immunolabelling also re-
vealed some nuclear staining in GM astrocytes. Some
cells expressing HSPB11 morphologically resembled
neurons, which were otherwise negative for HSPB1,
HSPB6 and HSPB8.
The expression of small HSPs is different between the
white and grey matter areas of leukocortical lesions
Leukocortical lesions affect both the deeper layers of the
GM and the adjacent WM. The GM parts are more in-
flammatory in comparison to subpial and intracortical
lesions, yet the number of activated HLA-DR+ microglia
is approximately 5 times lower than in the correspond-
ing WM part of the lesion [34, 35]. To analyse whether
a b c d e
f g h i j
k l m n o
p q r s t
Fig. 6 Expression pattern of the small HSP in cortical MS lesions. Grey matter from non-neurological cases and NAGM, intracortical demyelination
and subpial lesions from MS cases were double labelled with HLA-DR (pink) and the small HSPs (brown), HSPB1 (a), HSPB6 (b), HSPB8 (c) or
HSPB11 (d). Quantification revealed no correlation between the expression pattern of the small HSPs and cortical damage (A5, B5, C5, D5). NAGM
was compared versus the control, intracortical and subpial groups by the use of Mann-Whitney U test. Scale bar = 25 μm. CON = control, NAGM
= normal appearing grey matter, IC = intracortical, SP = subpial
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this difference is associated with an altered expression of
small HSPs, we evaluated leukocortical lesions from 5
MS patients.
While very similar numbers of HSPB1+ astrocytes
were found in control WM, control GM, NAWM and
NAGM (Fig. 7a), the number of HSPB1+ astrocytes
significantly increased in the WM part of the lesion
as compared to control WM and NAWM. Strikingly,
however, the numbers of HSPB1+ astrocytes in the
GM part of the lesion were about five times lower
than those found in the WM parts of the very same
lesions (p < 0.01, Fig. 7a). In addition, extracellular
structures in the WM part of the lesion but not the
GM part were clearly stained for HSPB1 as well
(Fig. 7e–g). A very similar result was obtained when
evaluating the expression of HSPB6. Again, HSPB6
expression in the WM part of the lesion was signifi-
cantly (p < 0.05) higher as compared to the GM part
(Fig. 7b, h–j). While evaluating HSPB8 staining, we
somewhat surprisingly found that already in control
GM samples or unaffected GM regions from MS pa-
tients, the frequency of HSPB8+ astrocytes was higher
than in WM regions. Still, and similar to the other
two small HSPs, the numbers of HSPB8+ astrocytes
were strongly increased in the WM but not the GM
part of leukocortical lesions (Fig. 7c). Evaluation of
the expression profile of HSPB11 demonstrated that
the very low levels of expression of HSPB11 did not
significantly change in either part of leukocortical
lesions (Fig. 7d), in line with the other data for
HSPB11 as described above.
Prompted by the striking differences in expression of
HSPB1, HSPB6 and HSPB8 in the WM versus GM part
of leukocortical MS lesions, we also examined HSPB5
for this particular feature. Similar to HSPB1 and HSPB6,
high expression levels of HSPB5 were restricted to the
WM part of the lesions (Fig. 7k, m). In line with previ-
ous data, HSPB5 expression in the WM part was found
not only in astrocytes, but also in oligodendrocytes
(Fig. 7o, p, q).
Subsets of astrocytes in MS lesions co-express small HSPs
To examine whether HSPB1, B5, B6 and B8 were in-
duced in the same subset of astrocytes we performed
double staining for combinations of HSPBs. These
studies revealed that while HSPB6 is already
expressed in the NAWM, subsets of astrocytes co-
express with HSPB1 and HSPB5 in active demyelinat-
ing lesions. However, some astrocytes were more in-
tensely stained with either only HSPB1 or HSPB5
(Fig. 8a–d). In contrast, all astrocytes expressing
HSPB8 co-localised with HSPB1, HSPB5 and HSPB6
in active MS lesions, yet a subset of astrocytes only
expressed HSPB8 (Fig. 8g–j). In the NAWM a small
percentage of astrocytes exclusively stained for HSPB8, all
astrocytes positive for HSPB6 were double labelled (data
not shown).
Discussion
Despite their generally recognized relevance to cellular
survival, cellular migration and to tissue remodelling
and repair [36, 37], surprisingly little is known about the
role of small HSPs in MS. With the exception of HSPB5,
only limited data are available on their expression pro-
files during the development of MS lesions, even though
such profiles may hold important clues to molecular fac-
tors involved in the disease process. In the present study,
we examined the expression of four small HSPs during
MS, and found significant increases in transcript levels
for HSPB1, HSPB6 and HSPB8 but not for HSPB11 in
NAWM from MS patients compared to white matter
from non-neurological controls. Immunohistochemical
studies revealed increased expression of HSPB1, HSPB6
and HSPB8 in actively demyelinating white matter MS
lesions, exclusively found in astrocytes.
Especially since the most prominent expression was ob-
served in the centre of chronic active lesions, astrocytic
expression of these small HSPs is most likely a secondary
response to lesion development. This sets these small
HSPs apart from another family member, viz. HSPB5
which is found in MS lesions at increased levels not only
(See figure on previous page.)
Fig. 7 Small HSP expression in leukocortical MS lesions. Expression of HSPB1 (a), HSPB6 (b), HSPB8 (c) and HSPB11 (d) was quantified in the white
matter (white bars) and grey matter (grey bars) area of leukocortical MS lesions compared to NAWM and NAGM in MS cases, and control white
and grey matter in controls. e A leukocortical lesion identified by a focal area of myelin loss depicted by PLP staining (brown). The border between WM
and GM is depicted by a black line (also in g, h and k). Immunohistochemistry shows the marked difference in HSPB1 expression in the WM and GM
parts of the LC lesion. f In the NAWM HSPB1 expression is limited to blood vessels (arrow). g Enlargement of area in (e) shows HSPB1 expression (pink) is
restricted to the white matter part of the lesion. h HSPB6 expression (brown) in an active leukocortical lesion containing HLA-DR+ microglia/macrophages
(pink) restricted to the WM part (i). HSPB6 is highly expressed in the WM part (i) and absent in the grey matter part (j). k A leukocortical lesion identified
by a focal area of myelin loss depicted by PLP staining (brown). HSPB5 (pink) is selectively expressed in oligodendrocytes in preactive lesions (data not
shown) in NAWM close to the WM/GM border (l, o), while in the active WM part (m) HSPB5 accumulates also in astrocytes (p) but not in the GM part of
the lesion (n, q). Statistical analysis (a–d) is performed by a Mann-Whitney U test, comparing white and grey matter groups with each
other (#) or comparing NAWM or NAGM with the control or lesion group (*) . # p < 0.05; ## p < 0.01; *p < 0.05. Scale bars e, h, k = 100 μm;
o–q = 50 μm; f–g, i–j, l–n = digitally zoomed in. CON = control, WM = white matter, GM = grey matter; NAWM = normal appearing white
matter, NAGM = normal appearing grey matter, LC = leukocortical lesions
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in astrocytes but also in oligodendrocytes [10–12, 14, 15]
(Additional file 1: Figure S1), and selectively accumulates
in oligodendrocytes already at the stage of preactive
lesions in the absence of infiltration or myelin damage.
The most striking finding of the present study, however, is
that the induction of small HSPs in astrocytes during le-
sion development in MS is restricted to WM and absent
from GM. This difference became particularly obvious by
examining the expression of small HSPs in leukocortical
lesions that extend over both regions. This finding
strongly suggests that the molecular signals that accom-
pany inflammatory demyelination in either region are dif-
ferent, inducing marked accumulation of small HSPs in
astrocytes in the WM but not in the GM.
Small HSPs are important for cell migration, differen-
tiation, and the regulation of autophagy and apoptosis
during embryonic development and tissue remodelling
in the brain. During MS, the prominent expression of
HSPB1, 5, 6 and 8 in astrocytes especially in chronic
active lesions is therefore likely a reflection of astrocytic
participation in tissue remodelling triggered by lesion
formation. An involvement of HSPB1 in tissue remodel-
ling and repair is supported for example by the observa-
tion that HSPB1-deficient mice display impaired wound
healing following excisional cutaneous wounds [38]. Also
in line with this notion are the many reports of
increased levels of small HSP in reactive astrocytes
following acute neurotrauma [39–42] and during
chronic neurodegenerative disease [43, 44]. Together
with our own findings, these data point to small HSP ex-
pression in astrocytes being a secondary response to
damage, and playing a role in controlling inflammation
and promoting tissue repair. It is of interest to note that
in their presently documented expression profiles,
HSPB1, 6 and 8 markedly differ from HSPB5. While
HSPB5 follows the same pattern of expression in astro-
cytes during lesion development in MS, it differs in
showing high expression in oligodendrocytes as well,
and doing so already in preactive MS lesions, even be-
fore leukocyte infiltration and myelin damage develops.
Such differences may help shed some light on the mo-
lecular factors that operate at different stages of lesion
development since in vitro studies indicate that small
HSPs respond in different ways to certain stressors.
While oxidative stress for example is an effective inducer
of HSPB5 in cultured rat oligodendrocytes, it fails to in-
duce HSPB1 [26, 45]. Similar differential responses by
small HSPs have been reported for astrocytes [13, 31]. In
active demyelinating lesions the majority of astrocytes
do express more than one small HSP. However variation
between subsets could be observed. Pathological studies
are only a snapshot in time, in vitro studies have docu-
mented differences in the time course of upregulation of
the various small HSPs [13, 23, 26, 45].
Our data on HSPB11 are different from the other
small HSPs in that HSPB11 was not induced during the
development of MS lesions. Also different from the
other small HSPs, we occasionally found somewhat
higher levels of HSPB11 in neurons. While HSPB11 is
apparently stress inducible in some cells and shares
structural homology to the other members of the family
of small HSPs, the classification of HSPB11 as a bona
fide small HSP is still under debate [20, 21]. Similar to
other family members, HSPB11 has been reported to in-
hibit apoptosis and reduce the neurotoxicity of amyloid
aggregates [46, 47] but marked differences in the neur-
onal expression profile of HSPB11 as compared to other
small HSPs have been reported before [26]. Our some-
what deviant results for HSPB11 are therefore in line
with previous reports.
Our finding that HSPB1, HSPB5, HSPB6 and HSPB8
all fail to be induced in MS lesions in GM regions, in-
cluding the GM part of leukocortical lesions, extends
previous reports of striking pathological differences be-
tween WM and GM demyelination in MS [3, 4, 34]. The
clear signs of blood-brain barrier disruption, leukocyte
influx and microglial activation that characterise actively
demyelinating WM lesions are absent from GM lesions,
indicating that important differences exist in the mo-
lecular make up between these lesions. Differences in
the local cell populations may help explain this. An obvi-
ous difference is the presence of large numbers of oligo-
dendrocytes and large amounts of myelin in WM, and of
neurons in GM, either of which may impact on the
course of inflammation. Oligodendrocytes for example
produce HSPB5 which impacts on the activation state of
microglia [15, 48], and myelin ingestion by microglia/
macrophages has similar regulatory effects [49, 50]. Also
neurons may influence local inflammatory processes
since they secrete a range of mediators that regulate
microglial activity, such as fraktalkine, IL-34 and extra-
cellular nucleotides [3, 51–53]. Not only signalling medi-
ators released during inflammation may therefore be
different between WM and GM lesions, differences may
also exist at the receiving end since protoplasmic astro-
cytes in the white matter have different origins from the
(See figure on previous page.)
Fig. 8 Double immunolabelling for combinations of different sHSPs. Representative images of active white matter lesions double labelled for
HSPB6 (pink) and HSPB1 (brown; a–b), HSPB6 (pink) and HSPB5 (brown; c–d), HSPB6 (pink) and HSPB8 (brown; e–f), HSPB1 (pink) and HSPB8 (brown; g–h)
and HSPB5 (pink) and HSPB8 (brown; i–j). Most astrocytes are double labelled, yet some show single staining; examples are indicated by the arrows. Scale
bar = 50 μm, b, d, f, h, j are digitally zoomed in
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fibrous astrocytes that are found in GM [54]. This may
additionally cause differential astrocyte expression pro-
files of small HSPs during inflammation, similar to
previously reported differences in the expression of S100
protein [55, 56].
Conclusion
Our data clarify that several small HSPs including
HSPB1, HSPB6 and HSPB8 are selectively induced in as-
trocytes as a secondary response to the development of
MS lesions in WM but not GM areas of the CNS. They
thus extend several previous reports on marked patho-
logical differences between WM and GM lesions in MS.
Since the induction of these small HSPs in astrocytes is
clearly secondary to damage rather than a primary event,
their differential induction in either area of the CNS
does not necessarily mean that WM and GM lesions are
driven by different pathogenic pathways. The difference
does suggest, however, that GM areas in an MS-affected
CNS benefit much less from the protective functions of
small HSPs than WM areas. This, in turn, may suggest
that therapeutic intervention involving augmentation of
the functions of small HSPs may be particularly helpful
to MS patients presenting with cortical damage.
Additional file
Additional file 1: Figure S1. Representative images of white matter tissues
from the same non-neurological control and MS cases as used to examine
expression of other small HSPs. Double immunohistochemistry staining for
HLA-DR (pink) and HSPB5 (brown). Control white matter (A) and NAWM
(B), NAWM surrounding a preactive lesion (C), preactive lesion (D), active lesion
(E), chronic active lesion (F- rim, G - centre) and inactive lesions (H) from MS
cases. Scale bar = 50μm (PDF 390 kb)
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